ライフサイエンスコーパス: exendin-4

1 mally to peripherally administered GLP-1 and exendin-4.

2 e signaling-1 (SOCS1)] were also elevated by exendin-4.

3 yntomodulin, and the clinically used mimetic exendin-4.

4 intravenous administration with ABP/TSTA-SP-exendin-4.

5 uated in vitro after delivery of ABP/TSTA-SP-exendin-4.

6 cit in ischemic rats treated with vehicle or exendin-4.

7 ted in 82% of the beta-cells pretreated with exendin-4.

8 MIN6B1 cells in response to the GLP-1 analog exendin-4.

9 in 86% of NOD mice treated with both CFA and exendin-4.

10 also essential for the protective effects of exendin-4.

11 pancreatectomy, low-dose streptozotocin, or exendin-4.

12 e motif, a 20-residue C-terminal sequence of exendin-4.

13 ificantly reduced in ob/ob-treated mice with Exendin-4.

14 in multiple system atrophy mice treated with exendin-4.

15 tion of fluorescence-labelled GLP-1 analogue exendin-4.

16 roup in the mutant receptor with the peptide exendin-4.

17 rents were no longer potentiated by GLP-1 or exendin-4.

18 ed in TTX, it was still enhanced by GLP-1 or exendin-4.

19 by 0.01-1 nmol/L GLP-1 and by 0.5-100 nmol/L exendin-4.

20 gn-3 blocked the proliferation stimulated by exendin-4.

21 administration of a GLP-1 receptor agonist, exendin-4.

22 administration of the GLP-1 receptor agonist exendin-4 (0.05 mug) significantly reduced cocaine, but

23 red the effect of repeated administration of exendin-4 (0.5 mug/kg, intraperitoneal twice a day for 7

24 GLP-1-(7-36)-amide and exendin-4-(1-39) are glucagon-like peptide-1 (GLP-1) rec

25 ent GLP-1 receptor antagonist, des His1 Glu9 exendin-4 (10.0 microgram), significantly attenuated LiC

26 or their lean littermates, were treated with Exendin-4 [10 microg/kg or 20 microg/kg] for 60 days.

27 tion of (111)In-[Lys40(Ahx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinom

28 Unlike the radiometal-labeled exendin-4, (18)F-TTCO-Cys(40)-exendin-4 has much lower k

29 pre-administration of the GLP-1R antagonist Exendin-4(3-39).

30 ng with [Nle(14),Lys(40)(Ahx-DOTA-(68)Ga)NH2]exendin-4 ((68)Ga-DOTA-exendin-4) is feasible and sensit

31 r smad 2 and/or smad 3, as well as exogenous exendin-4 (a long-acting glucagon-like peptide-1 agonist

32 Exendin-4, a 39 amino acid peptide originally isolated f

33 Serotonin depletion impaired the ability of exendin-4, a clinically used GLP-1 analog, to reduce bod

34 ides made up of glucagon and either GLP-1 or exendin-4, a GLP-1 agonist, was engineered.

35 We studied effects of GLP-1 and exendin-4, a GLP-1 receptor agonist, on gamma-aminobutyr

36 n of the beta-cell toxin streptozotocin, and exendin-4, a glucagon-like peptide 1 (GLP-1) agonist.

37 (mGluR) agents in relation to the effects of exendin-4, a glucagon-like peptide 1 analogue, cholecyst

38 Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor ag

39 Here we investigated whether the addition of exendin-4, a hormone that stimulates insulin secretion a

40 Here we report that exendin-4, a long-acting GLP-I agonist, stimulates both

41 diabetic NOD mice were treated with CFA and exendin-4, a potent analog of glucagon-like peptide-1.

42 In the micelle-bound state of exendin-4, a single helix (residues 11-27) is observed w

43 te that the glucagon-like peptide-1 analogue exendin-4, a well-tolerated and Federal Drug Agency-appr

44 nt of overtly diabetic NOD mice with ALS and exendin-4 achieved complete remission in 23 of 26 mice (

45 exia and body weight loss induced by central exendin-4 administration in a rat.

46 Increased HPFv GLP-1R activity following exendin-4 administration potently reduced food intake (b

47 in Glp1r(-/-) recipient mice, whereas acute exendin-4 administration robustly induced the expression

48 No treatment or exendin-4 alone failed to produce remission.

49 While central infusion of des His1 Glu9 exendin-4 also blocked GLP-1-induced (10.0 microgram) an

50 o short-term treatment with the GLP-1 analog exendin-4 also declined with age.

51 Exendin-4, also, has a longer half-life than GLP-1, due

52 Exendin-4, an analog of GLP-1, in some critical experime

53 was triggered by the GLP-1 receptor agonist exendin-4, an effect mimicked by caffeine, Sp-cAMPS or f

54 pared with the stable GLP-1 and CCK mimetics exendin-4 and (pGlu-Gln)-CCK-8, respectively.

55 )NH2]exendin-4, and [Lys40-(AHX-DFO-89Zr)NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 perfo

56 The GLP-1 effects were mimicked by exendin-4 and antagonized by exendin-9-39.

57 ve determined the structuring preferences of exendin-4 and GLP-1 by NMR in both the solution and dode

58 and duration of glucose-lowering effects of exendin-4 and GLP-1 in hyperglycemic db/db and ob/ob mic

59 2 (Skp2) were assessed in mice treated with exendin-4 and in a mouse model with specific upregulatio

60 erance effects of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse li

61 Met-303 was more important for exendin-4 and oxyntomodulin action than those of GLP-1 p

62 nding and signaling of the peptide mimetics, exendin-4 and oxyntomodulin, as well as small molecule a

63 Peptides, including glucagon-like peptide-1/exendin-4 and the combination of epidermal growth factor

64 The coapplication of exogenous exendin-4 and, specifically, low-dose exogenous TGF-beta

65 eference compound [Lys40-(AHX-DTPA-111In)NH2]exendin-4 and, thus, represent potential new tracers for

66 ceptor affinity for [Lys40-(AHX-DFO-68Ga)NH2]exendin-4, and [Lys40-(AHX-DFO-89Zr)NH2]exendin-4 and [L

67 N171-82Q HD mice were treated with insulin, Exendin-4, and the newly developed GLP-1-Tf to determine

68 In conclusion, Exendin-4 appears to effectively reverse hepatic steatos

69 We therefore propose that GLP-1 and exendin-4 are capable of causing pancreatic precursor ce

70 These data indicate that helodermin and exendin-4 are not the precursors to VIP and GLP-1 and th

71 To determine whether helodermin and exendin-4 are present in mammals and their evolutionary

72 entire amino acid sequence of helodermin and exendin-4, as well as a 44- or 45-amino acid N-terminal

73 ynomolgus pancreas after coinjection of DO3A-exendin-4 at 0.15-20 mug/kg ranged from 49% to 97%, as e

74 arable to that of [Lys40-(AHX-DTPA-111In)NH2]exendin-4 at 1-48 h after injection.

75 90% (P < 0.0001) by coadministration of DO3A-exendin-4 at 100 mug/kg.

76 n of the kidneys, a known characteristic for exendin-4-based radiotracers.

77 trast, no tertiary structure is evident when exendin-4 binds to DPC micelles.

78 G-protein signalling comparable to GLP-1 and Exendin-4, but exhibited a significantly reduced beta-ar

79 mitotic effector) observed after exposure to exendin-4, but not that of PDX-1 or VEGF-A/C.

80 was predicted to be important for GLP-1- and exendin-4-, but not oxyntomodulin-mediated cAMP formatio

81 In rodents, and possibly in humans, exendin-4 can stimulate beta-cell proliferation.

82 livary gland expression, that helodermin and exendin-4 coevolved to serve a separate specialized func

83 Toward this goal, we synthesized an exendin-4 conjugated magnetic iron oxide-based nanoparti

84 Although exendin-4 could also stimulate actin remodeling, this wa

85 In Tg mice, exendin-4 decreased levels of hippocampal IRS-1pSer and

86 (18)F-TTCO-Cys(40)-exendin-4 demonstrated its great potential for transplan

87 (18)F-TTCO-Cys(40)-exendin-4 demonstrated specific binding to GLP-1R.

88 An exendin-4 derivative conjugated to desferrioxamine (DFO)

89 emonstrated the potential of radiometallated exendin-4 derivatives for the imaging of glucagonlike pe

90 The aim of this work was the development of exendin-4 derivatives for the imaging of insulinomas by

91 Recently investigated exendin-4 derivatives were radiolabeled with the SPECT i

92 ze, and likely do not involve nausea as HPFv exendin-4 did not induce a conditioned flavor avoidance.

93 Exendin-4 dose-dependently accelerated glucose lowering

94 ata indicate that GLP-1 is less helical than exendin-4 due to the presence of Gly16; chemical shift d

95 activity led to a more potent attenuation of exendin-4 effects on food intake.

96 Exendin-4 enhanced the effect of CFA on reversing diabet

97 eptide-1 (GLP-1) and the long-acting agonist exendin 4 (Ex-4) expand beta-cell mass by stimulating ne

98 a 2-week administration of the GLP-1 analog exendin 4 (ex-4) induced an almost complete ablation of

99 agon-like-peptide-1 (GLP-1) receptor agonist exendin-4 (Ex-4) and was accompanied by quantal secretor

100 Treatment with exendin-4 (Ex-4) delivered by subcutaneous micro-osmotic

101 c voltammetry showed that the GLP-1R agonist exendin-4 (Ex-4) does not alter dopamine release in the

102 Exendin-4 (Ex-4), a GLP-1 receptor agonist, was then fus

103 Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) rece

104 We found that exendin-4 (Ex-4), an agonist of the glucagon-like peptid

105 he GLP-1 receptor agonist and cAMP stimulus, exendin-4 (Ex-4), could rescue beta-cell replication and

106 on of a pancreatic beta-cell trophic factor, exendin-4 (Ex-4), during the prediabetic neonatal period

107 long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of anti

108 toneal administration of the GLP-1R agonist, exendin-4 (Ex-4), on food intake in OP and obese-resista

109 ic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be ac

110 or the more stable exogenous GLP-1R agonist exendin-4 (Ex-4).

111 the glucagon-like peptide-1 receptor agonist Exendin 4 (Ex4) protects hepatocytes from ischemia reper

112 , icv infusion of the GLP-1 receptor agonist exendin 4 (Ex4) reduced insulin-stimulated muscle glucos

113 Evans rats were monitored for BW loss during exendin-4 (Ex4) administration.

114 In this study, we demonstrate a smart exendin-4 (Ex4) delivery device based on microneedle (MN

115 involving direct effects of a GLP-1 agonist, Exendin-4 (EX4) on food reward that are exerted at the l

116 Exendin-4 (Ex4), a glucagon-like peptide-1 receptor (GLP

117 Because exendin-4 (Ex4), a long acting glucagon-like peptide 1 r

118 intra-PVT delivery of either GLP-1R agonist, exendin-4 (Ex4), or GLP-1R antagonist, exendin-9-39 (Ex9

119 intraperitoneal injection of either GLP-1 or Exendin-4 (Ex4; a GLP-1 receptor agonist).

120 We report that GLP-1 and its agonist, exendin-4 (Exd4), induce Wnt signaling in pancreatic bet

121 ndle structure of GLP1R bound to the peptide Exendin-4 (Exe4; a GLP1R agonist on the market for treat

122 nal transport, were prevented by exposure to exendin-4 (exenatide), an anti-diabetes agent.

123 a- and 89Zr-radiolabeled [Lys40-(AHX-DFO)NH2]exendin-4 exhibit characteristics comparable or superior

124 bution experiments, [Lys40-(AHX-DFO-68Ga)NH2]exendin-4 exhibited a significantly enhanced tumor uptak

125 An exendin-4 expression system was constructed using the tw

126 TSTA exendin-4 expression system with SP and ABP polymer has

127 se (CICR), and cAMP-elevating agents such as exendin-4 facilitate CICR in beta-cells by activating bo

128 /scatter factor, betacellulin, activin A, or exendin-4 failed to induce pancreatic and duodenal homeo

129 type 2 diabetes, the daily administration of exendin-4 for 10 days post-pancreatectomy attenuates the

130 one, or (pGlu-Gln)-CCK-8 in combination with exendin-4 for 21 days to high-fat-fed mice significantly

131 th the glucagon-like peptide (GLP)-1 analog, exendin-4, for 12 weeks induced the expansion of PDGs wi

132 l or aqueous glycol, the Leu21-Pro38 span of exendin-4 forms a compact tertiary fold (the Trp-cage) w

133 Both helodermin and exendin-4 full-length cDNAs were approximately 500 base

134 In this study, we demonstrate that exendin-4/GLP-1 has a cognate receptor on human hepatocy

135 g may represent a novel downstream target of exendin-4 (glucagon-like peptide 1) signaling and potent

136 Exendin-4, glucagon-like peptide 1 (GLP-1) receptor agon

137 Increased expression of exendin-4, glucose dependent insulin secretion in NIT-1

138 ic GLP-1R activation with the GLP-1R agonist exendin-4 had no effect on food intake, hindbrain c-fos

139 gnate receptor on human hepatocytes and that exendin-4 has a direct effect on the reduction of hepati

140 Exendin-4 has a helix-favoring glutamate as residue 16.

141 Exendin-4 has a more regular and less fluxional helix in

142 Unlike GLP-1, exendin-4 has a prolonged glucose-lowering action in viv

143 In addition, the diabetes drug exendin-4 has been associated with pancreatitis, whereas

144 clusion, acute and chronic administration of exendin-4 has demonstrated an antidiabetic effect in sev

145 ometal-labeled exendin-4, (18)F-TTCO-Cys(40)-exendin-4 has much lower kidney uptake.

146 Furthermore, it appears that exendin-4 has the same beneficial effects in vitro as th

147 When the Trp-cage forms, fraying of the exendin-4 helix occurs exclusively from the N-terminus;

148 HbA1c was reduced in the (pGlu-Gln)-CCK-8/exendin-4 hybrid and combined parent peptide treatment g

149 rapeutic utility of a novel (pGlu-Gln)-CCK-8/exendin-4 hybrid peptide compared with the stable GLP-1

150 administration of the novel (pGlu-Gln)-CCK-8/exendin-4 hybrid, (pGlu-Gln)-CCK-8 alone, or (pGlu-Gln)-

151 rred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.

152 All patients underwent (111)In-DTPA-exendin-4 imaging, 25 patients underwent surgery (with h

153 Exendin-4 improved insulin sensitivity in ob/ob mice, as

154 al mediator of beta-cell loss and shows that exendin-4 improves cell survival via restoration of lyso

155 Here, we developed an (18)F-labeled exendin-4 in high specific activity for islet imaging by

156 With the exception of exendin-4 in media containing fluoro alcohol cosolvents,

157 opic glutamate receptor (mGluR) agonists and exendin-4 in the brainstem.

158 fects of the glucagon-like peptide-1 agonist exendin-4 in transgenic mice paves the way for translati

159 Thus, to improve the activity of exendin-4 in vivo, gene therapy system was developed as

160 do not affect stimulation by GLP-1, GIP, or exendin-4 in wild-type islets, although they block phosp

161 we report that GLP-1 and its stable analogue exendin-4 increase the action potential firing frequency

162 Exendin-4 increased acute-phase insulin release to a sim

163 Exendin-4 increased cAMP accumulation in purified IELs a

164 In cultured islets, exendin-4 increased cyclin A2 and Skp2 and reduced p27.

165 Exendin-4 increased the phosphorylation of 3-phosphoinos

166 rones where L-AP4 decreased mIPSC frequency, exendin-4 increased, while PP had no effect upon, mIPSC

167 iled to expand beta-cell mass in response to exendin-4, indicating that p16(Ink4a)levels are a critic

168 tor receptor (EGFR) null mouse, we show that exendin-4 induced an increase in proliferation and beta-

169 Exendin-4 induced proproliferative signaling pathways in

170 In voltage clamp, the GLP-1 agonist Exn4 (exendin-4) induced an inward current that reversed near

171 Ex vivo analyses show prolonged exendin-4-induced activation (live cell calcium signalin

172 -positive differentiation seems to entail an exendin-4-induced drop in smad 2 and elevation in smad 3

173 moted, whereas 26RFa inhibited, glucose- and exendin-4-induced insulin secretion, through Galphas and

174 Oligonucleotides anti-miR-7 inhibited the exendin-4-induced proliferation in normal rat cholangioc

175 kolin or the glucagon-like peptide 1 mimetic Exendin-4, inhibits the shuttling of MondoA and potently

176 Exendin-4 is a 39 amino acid peptide isolated from the s

177 Exendin-4 is a GLP-1 agonist that is clinically used for

178 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-

179 Exendin-4 is a peptide agonist of the glucagon-like pept

180 This sensitizing action of exendin-4 is diminished by an inhibitor of PKA (H-89) or

181 Exendin-4 is used to clinically improve glucose toleranc

182 ed Ca2+ (NP-EGTA), a GLP-1 receptor agonist (exendin-4) is demonstrated to sensitize intracellular Ca

183 )(Ahx-DOTA-(68)Ga)NH2]exendin-4 ((68)Ga-DOTA-exendin-4) is feasible and sensitive in detecting benign

184 udy, we found that the potency of GLP-1, not exendin 4, is specifically enhanced by the endocannabino

185 pancreata of Pdx1-Cre; LSL-Kras(G12D) mice, exendin-4 led to acceleration of the disruption of exocr

186 copy confirmed that the peptides maintain an exendin-4-like structure with its characteristic tryptop

187 ion of a fluorophore-labeled GLP-1R agonist, exendin-4, localizes within astrocytes and neurons in th

188 The Leu21-Pro38 segment of exendin-4 may be the smallest protein-like folding unit

189 bally, ECL2 mutation was more detrimental to exendin-4-mediated Ca(2+)i release than GLP-1(7-36)-NH(2

190 Exendin-4 microinjections increased plasma insulin.

191 MP signaling, of the incretin hormone analog exendin-4 on cell cycle regulation in beta-cells.

192 of DXM, amplified the stimulatory effect of exendin-4 on GSIS.

193 the role of EGFR signaling in the effects of exendin-4 on the control of blood glucose metabolism and

194 0.1, 1 nmol/L GLP-1 or 10, 50, or 100 nmol/L exendin-4, only the sIPSC frequency increased.

195 educed dietary fat along with PEG-leptin and exendin-4 or FGF21 cotreatment.

196 ated (PEG)-leptin analog in combination with exendin-4 or FGF21.

197 Exendin-4 or GLP-1-Tf (but not insulin) treatment also i

198 n content was increased in mice treated with exendin-4 or liraglutide.

199 h the glucagon-like peptide 1 (GLP-1) analog exendin-4, or after streptozotocin (STZ) administration.

200 NH2]exendin-4 and [Lys40-(AHX-DTPA-111In)NH2]exendin-4 performed similarly well.

201 (68)Ga-DOTA-exendin-4 PET/CT and (111)In-DOTA-exendin-4 SPECT/CT wer

202 (68)Ga-DOTA-exendin-4 PET/CT correctly identified the insulinoma in

203 ary data suggest that the use of (68)Ga-DOTA-exendin-4 PET/CT in detecting hidden insulinomas is feas

204 fused surgery despite a positive (68)Ga-DOTA-exendin-4 PET/CT scan.

205 of a clinically used GLP-1 receptor agonist, exendin-4, potently increased the expression of IL-6 in

206 er loss of endothelial GLP-1R expression and exendin-4-protective actions and exhibited more albuminu

207 It is concluded that exendin-4 protects the CNS from damage due to cerebral i

208 Treatment with exendin-4 quantitatively reduced triglyceride stores com

209 Furthermore, the GLP-1 receptor agonist exendin-4 reduced CP-induced renal injury and apoptosis,

210 d into mice cured by treatment with ALS plus exendin-4 remained intact, and cotransfer of lymphocytes

211 with most doses of GLP-1, the same doses of exendin-4 resulted in a similar glucose-lowering effect

212 Intraperitoneal administration of exendin-4 resulted in extensive FOS expression in areas

213 ed into the selective GLP-1 receptor agonist exendin-4, resulting in hybrid peptides with potent dual

214 Cotreatment with the GLP-1 receptor agonist exendin-4 reversed the lysosomal dysfunction, relieving

215 vered mammalian homologues to helodermin and exendin-4 seems unlikely.

216 CC agonist 2a and the Glp-1 receptor agonist Exendin-4 showed an additive effect on beta-cell replica

217 Mice treated with exendin-4 showed increased beta-cell proliferation, elev

218 rgistic and codependent relationship between exendin-4 signaling and TGF-beta isoform signaling.

219 nd cDNA libraries with either helodermin- or exendin-4-specific cDNAs failed to identify evidence for

220 (111)In-DTPA-exendin-4 SPECT/CT correctly detected 19 insulinomas and

221 oma in 4 of 4 patients, whereas (111)In-DOTA-exendin-4 SPECT/CT correctly identified the insulinoma i

222 (111)In-DTPA-exendin-4 SPECT/CT could provide a good second-line imag

223 For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI

224 (111)In-DOTA-exendin-4 SPECT/CT has been shown to be highly efficient

225 68)Ga-DOTA-exendin-4 PET/CT and (111)In-DOTA-exendin-4 SPECT/CT were performed in a randomized cross-

226 ntified in separate patients by (111)In-DTPA-exendin-4 SPECT/CT.

227 Moreover, administration of GLP-1 agonist exendin-4 stimulated beta-cell proliferation in young bu

228 Exendin-4 stimulated cyclin A2 promoter activity via the

229 PDX-1 knockdown reduced exendin-4-stimulated cAMP synthesis and cyclin A2 transc

230 Antagonist 5d not only blocked exendin-4-stimulated insulin release in islets but also

231 In Min6 cells, cyclin A2 knockdown prevented exendin-4-stimulated proliferation.

232 A2 is required for beta-cell proliferation, exendin-4 stimulates cyclin A2 expression via the cAMP p

233 We show that exendin-4 stimulates the regeneration of the pancreas an

234 clin A2 expression via the cAMP pathway, and exendin-4 stimulation of cAMP requires PDX-1.

235 mia and lowering haemoglobin A1c levels than Exendin-4, suggesting that GLP-1R G-protein-biased agoni

236 rglycemia is normalized in mice treated with exendin-4, suggesting that this model can be effectively

237 These results show that exendin-4 synergistically augments the remission-inducin

238 ne expression in mice disrupts the action of exendin-4 to facilitate CICR in the beta-cells of these

239 This action of exendin-4 to facilitate CICR was reproduced by cAMP anal

240 naesthetized rat preparation, application of exendin-4 to the DVC decreased gastric tone in a concent

241 hx-DTPA-(111)In)NH2]-exendin-4 ((111)In-DTPA-exendin-4) to identify insulinomas.

242 1 potency more than 40-fold, but not that of exendin 4, to stimulate cAMP production.

243 ddition of beta-cell growth factors, such as exendin-4, to immunotherapy protocols with anti-T-cell a

244 patic steatosis was significantly reduced in Exendin-4 treated ob/ob mice.

245 oxidative stress parameters were improved in exendin-4 treated rats compared to control.

246 Results indicate that exendin-4 treated rats had significant protection follow

247 3 mg/kg) on cerebral ischemia in control and exendin-4 treated rats.

248 cerebral ischemia was similar in vehicle or exendin-4 treated rats.

249 d 8) mRNAs were specifically up-regulated in exendin-4-treated AR42J cells.

250 endin-4 was also observed in the ABP/TSTA/SP-exendin-4-treated mice groups, compared with the others

251 cerebral ischemia which was not affected by exendin-4 treatment or by BQ123 administration.

252 Combining CFA with exendin-4 treatment significantly increased the insulin

253 Exendin-4 treatment was also associated in each of these

254 ulin-positive differentiation in response to exendin-4 treatment, suggesting a role for BMP signaling

255 ke and body weight in response to peripheral exendin-4 treatment.

256 a reduction in the net weight gained during Exendin-4 treatment.

257 Helodermin and exendin-4, two peptides isolated from the salivary gland

258 usly twice daily for 5-6 weeks with doses of exendin-4 up to 100 microg x rat(-1) x day(-1) (approxim

259 strongly support the notion that (68)Ga-DO3A-exendin-4 uptake in the pancreas is mediated by specific

260 Exendin-4 was 5,530-fold more potent than GLP-1 in db/db

261 The highest insulinotropic effect of exendin-4 was also observed in the ABP/TSTA/SP-exendin-4

262 systemically administered fluorophore-tagged exendin-4 was blocked by central pretreatment with the c

263 Tumor uptake of [Lys40-(AHX-DFO-89Zr)NH2]exendin-4 was comparable to that of [Lys40-(AHX-DTPA-111

264 In the present study, (68)Ga-labeled exendin-4 was evaluated for PET imaging and quantificati

265 F-tetrazine trans-cyclooctene (TTCO)-Cys(40)-exendin-4 was evaluated in vitro with INS-1 cell and in

266 [Lys40-(AHX-DFO)NH2]exendin-4 was labeled with 89Zr and 68Ga in high radioch

267 (18)F-TTCO-Cys(40)-exendin-4 was obtained in high specific activity and cou

268 ntial efficacies in the CICR assay such that exendin-4 was partly effective, 6-Bnz-cAMP-AM was fully

269 nically evaluated [Lys40-(AHX-DTPA-111In)NH2]exendin-4 was used as a reference compound.

270 Based on the amino acid sequence of exendin-4, we created a neopeptide via introduction of a

271 further improve the therapeutic efficacy of exendin-4, we have developed a novel peptide engineering

272 ymethylaza)cyclododecane-10-azaacetyl (DO3A)-exendin-4 were performed in rats (organ distribution) an

273 The gastroinhibitory effects of exendin-4 were unaffected by systemic pretreatment with

274 the glucagon-like peptide-1 receptor agonist exendin-4 were unchanged.

275 st 8-Br-Rp-cAMPS blocked CICR in response to exendin-4, whereas the PKA inhibitor H-89 was ineffectiv

276 macological treatments with the GLP-1 analog Exendin-4, which increased nuclear Hes3 localization.

277 Tetrazine ligation was used to radiolabel exendin-4 with (18)F.

278 ch is composed of pbeta-Gal4-p65 and pUAS-SP-exendin-4 with combining the advantages of signal peptid

279 y was to determine whether administration of Exendin-4 would reverse hepatic steatosis in ob/ob mice.